Middle East and Africa Neurological Biomarker Market

Market Introduction

Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. This helps in the previous detection of disease, less invasive diagnostics, allows faster drug development, and is expected to be the effective treatment.

Middle East and Africa Neurological Biomarker Strategic Insights

Strategic insights for the Middle East and Africa Neurological Biomarker provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Neurological Biomarker Report Scope

Middle East and Africa Neurological Biomarker Regional Insights

The geographic scope of the Middle East and Africa Neurological Biomarker refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Middle East and Africa neurological biomarker market is expected to reach US$ 529.04 million by 2027 from US$ 232.80 million in 2019; it is estimated to grow with a CAGR of 11.0% from 2020 to 2027. The growth of the market is attributed to some key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with use of biomarkers such as the absence of pre-analytical tests are one of the major factors likely to hinder the market growth during the forecast period.

Key Market Segments

The Middle East and Africa neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.

Based on application, the Middle East and Africa neurological biomarker market is segmented into Alzheimer’s disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer’s disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 to 2027.

The Middle East and Africa neurological biomarker market, by end user, is segmented into pharmaceutical & biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical and biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.

Major Sources and Companies Listed

A Few of the primary and secondary sources associated with this report on the Middle East and Africa neurological biomarker market are the African Journal of Neurological Sciences (AJNS), Bank Melli Iran (BMI), Rare Diseases South Africa (RDSA) and BMC Neurology.

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of the Middle East and Africa neurological biomarker market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Middle East and Africa neurological biomarker market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Middle East and Africa neurological biomarker market.

MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKER SEGMENTATION

By Product

• Proteomics Biomarker
• Genomics Biomarker
• Metabolomics Biomarker
• Imaging Biomarker
• Others

By Application

• Alzheimer’s Disease
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Spinal Muscular Atrophy
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostics
• Research Organizations

By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East and Africa

Company Profiles

• Thermo Fisher Scientific Inc.
• Abbott
• Bio-Rad Laboratories Inc.
• QIAGEN
• Immunarray Pvt. Ltd.
• Quest Diagnostics Incorporated
• Perkin Elmer, Inc
• MERCK KGaA